By offering all the culture protocols and materials sourcing information for our models through this OpenLiver initiative, we hope to enable researchers across the pharmaceutical and biotech community to more easily compare results within and between labs.
WHITEHOUSE, N.J. (PRWEB) February 14, 2019
This year’s conference in Baltimore will bring together over 315 companies from around-the-world and will host 80 scientific sessions and 2,100 presentations. Given SOT’s mission to bring together researchers from all facets of the toxicology research space, Visikol will feature its OpenLiver™ 3D cell culture model initiative that it recently launched with Biopredic International. As a leader in 3D cell culture assays, Visikol has launched the OpenLiver initiative to provide researchers with access to open source liver 3D cell culture models of varying complexities such that consensus surrounding appropriate model choice for evaluating mechanisms of toxicity and studying liver-related diseases (e.g. NASH, NAFLD) may be generated.
“By offering all the culture protocols and material sourcing information for our models through this OpenLiver initiative, we hope to enable researchers across the pharmaceutical and biotech community to more easily compare results within and between labs. We want to get everyone on the same page with the types of models that are being used for disease modeling and liver toxicity questions so that multiple labs can compare results and the field can establish consensus,” described Visikol Director of In Vitro Studies Dr. Erin Edwards. During the conference, Visikol we be hosting a talk by Chief Science Officer Dr. Thomas Villani titled Building Consensus in the Liver 3D Cell Culture Field Through Open Source Models. The talk will take place on 3/11 from 9-10:00 AM in room 339.
In this session, Visikol will discuss how it has developed open source liver 3D cell culture models for use in routine toxicity studies as well as more complex investigations into disease pathology, beginning with an in-depth discussion of the OpenLiver HepaRG™ NP 3D model. Additionally, participants will learn how cost, throughput, and in vivo relevancy can be optimized by varying the complexity of liver 3D cell culture models implemented.
Additionally, Visikol will be presenting a poster at SOT this year titled Complete Characterization of Cell Death in 3D Cell Culture Models for Toxicity Profiling (3074/ P611) on 3/13. To discuss your next research project, stop by booth 3225.
Visikol is a CRO focused on advanced drug discovery that is leading the fields of bio-imaging, bioinformatics and image analysis. We conduct end-to-end drug discovery services that include both 2D and 3D in vitro models and assays, 3D whole mount tissue imaging, digital pathology and custom drug discovery projects. Visikol offers a portfolio of drug discovery services ranging from 2D and 3D cell culture model and assay development to in vitro screening, animal tissue histology and automated image processing. The focus of these services is to transform tissues into images and ultimately into quantitative data sets that can be mined for actionable insights that help our Clients make more informed decisions during the drug discovery process. Additionally, Visikol manufactures and sells a suite of tissue clearing reagents and 3D immuno-labeling kits. These products allow researchers to easily and rapidly image whole tissues and 3D cell culture models in 3D instead of traditional 2D sectioning. For more information about Visikol or its services, please visit our website at visikol.com.